Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin

Hepatology

Volumn 54, Issue 5, 2011, Pages 1518-1526

  Scherzer, Thomas Matthias ^a   Stättermayer, Albert Friedrich ^a   Strasser, Michael ^b   Laferl, Hermann ^c   Maieron, Andreas ^d   Stauber, Rudolf ^e   Datz, Christian ^a   Dulic Lakovic, Emina ^f   Steindl Munda, Petra ^a   Hofer, Harald ^a   Ferenci, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; EARLY VIROLOGIC RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAPID VIROLOGIC RESPONSE; RECURRENCE RISK; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG MONITORING; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 80055047790     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24546     Document Type: Article

References (33)

1. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954-960.
2. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
3. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-458.
4. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. HEPATOLOGY 2008; 47: 43-50.
5. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. HEPATOLOGY 2008; 47: 1884-1893.
6. Lee S, Sherman M, Ramji A, Greenbloom S, Elkashab M, Pluta H, et al. 36 versus 48 weeks of treatment with peginterferon alfa-2a plus ribavirin for genotype 1/4 patients with undetectable HCV RNA at week 8: final results of a randomized controlled trial. HEPATOLOGY 2010; 52(Suppl 1): 359A [Abstract 79].
7. Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, et al. Completely individualized treatment durations (24, 30, 36, 42, 48, 60 or 72 weeks) with peginterferon-alfa-2b and ribavirin in HCV genotype 1-infected patients (INDIV-2 study). J Hepatol 2010; 52(Suppl 1): S25-S26 [Abstract 54].
8. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097.
9. Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-460.
10. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. HEPATOLOGY 2007; 46: 1688-1694.
11. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. HEPATOLOGY 2010; 52: 1201-1207.
12. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138: 503-512.
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
14. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
15. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
16. Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-350.
17. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus patients. Gastroenterology 2010; 139: 120-129.
18. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
19. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
20. Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, Steindl-Munda P, et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011; 54: 866-71.
21. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421.
22. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865-1876.
23. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1592.
24. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433.
25. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031.
26. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. HEPATOLOGY 2010; 52: 1888-1896.
27. Jacobson IM, McHutchison JG, Dusheiko GM, Di Bisceglie AM, Reddy R, Bzowej NH, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study. HEPATOLOGY 2010; 52(Suppl 1): 427A [Abstract 211].
28. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
29. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
30. Foster GR, Zeuzem S, Andreone A, Pol S, Lawitz E, Diago M, et al. Telaprevir-based therapy in genotype 1 hepatitis c virus-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results. Hepatol Int 2011; 5: 14 [Abstract CS4].
31. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S. Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med 2011; 364: 1207-1217.
32. Mangia A, Thompson AJ, Santoro, Piazzolla E, Copetti M, Minerva N, et al. Limited utility of IL28B in the setting of response-guided treatment with detailed on treatment virological monitoring. HEPATOLOGY 2011 [Epub ahead of print].
33. Zeuzem S, Arora S, Bacon B, Box T, charlton M, Diago M, et al. Pegylated interferon lambda (PEGIFN-λ) shows superior viral response with improved safety and tolerability versus PEGIFN-α-2a in HCV patients (G1/2/3/4): EMERGE phase IIb through week 12 [Abstract]. J Hepatol 2011; 54(Suppl 1): S538-S539.